Dana-Farber News (@DanaFarberNews)
@DanaFarberNews
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu
611 正在关注 6.2K 粉丝
New in @NEJM: Phase 3 LITESPARK-022 showed belzutifan + pembrolizumab significantly improved disease-free survival in high-risk kidney cancer after surgery. The FDA recently approved the combo in this patient population. Study lead @DrChoueiri of @DanaFarber explains:
显示更多
Next-generation HIF-2α inhibitor casdatifan shows promising signs of on-target efficacy in first-in-patient clinical trial in metastatic clear cell kidney cancer. Now published in @Nature and led by @DrChoueiri. @DanaFarber_GU
➡️
显示更多
